All In MedTech

Device Trial Radar · NCT05147571

RNS System NAUTILUS Study

RNS® System Responsive Thalamic Stimulation for Primary Generalized Seizures (NAUTILUS) Study

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 9, 2022

Primary completion

Apr 4, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
NeuroPaceNot on our public-company list
Sponsor type
Industry
First posted
Dec 7, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.

Conditions

  • Epilepsy
  • Idiopathic Generalized Epilepsy
  • Generalized Tonic Clonic Seizure

Interventions

  • Responsive stimulationDevice

    The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

  • Sham stimulationDevice

    For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-week post-operative serious device-related adverse event (SADE) rateTime frame: 84 days post-implant (12 weeks)
  2. Time to second generalized tonic-clonic (GTC) seizureTime frame: 9-month Effectiveness Evaluation Period

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • University of Colorado

    Aurora, Colorado

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.